Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled Phase 2 study of deutetrabenazine for moderate to severe tardive dyskinesia
2014-001890-15Phase 2Completed
- Sponsor
- Auspex Pharmaceuticals
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in tardive dyskinesia (TD) comparing Deutetrabenazine with Placebo (2 arms). Primary endpoint: Change in AIMS score (Items 1–7) from baseline to Week 12. Started Aug 2014; status: completed.
02
Drugs
deutetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on 2014-001890-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001890-15.